TRIM21 E3 Ligase Reprogramming for Cancer Therapy | The Mark Foundation for Cancer Research Molecular glue degraders that recruit E3 ubiquitin ligases have transformed the treatment of certain hematologic malignancies, yet their broader application to solid tumors has been limited by the…

#TRIM21 E3 Ligase Reprogramming for #Cancer Therapy: themarkfoundation.org/portfolio/tr...

Convergen Raises $10 Million to Propel TrimTAC Platform for Neurodegenerative Disease Solutions Convergen has closed a $10 million seed funding round to enhance its TrimTAC platform aimed at treating neurodegenerative disorders. The funding will help tackle critical challenges in targeted protein degradation.

Convergen Raises $10 Million to Propel TrimTAC Platform for Neurodegenerative Disease Solutions #China #Suzhou #Convergen #TrimTAC #TRIM21

The crystal structure of the murine TRIM21 PRYSPRY domain in complex with suramin was solved at 1.3 Å resolution. This video shows the conformational changes upon suramin binding. #TRIM21 #E3Ligases #CrystalStructure doi.org/10.1107/S205...